Turn Therapeutics Inc. (TTRX) Balance Sheet
TTRX balance sheet, 2025
December 31, 2025 · U.S. dollars$12.2M assets = $7.5M liabilities + $4.7M equity
Both columns are drawn to the same scale: what TTRX owns equals what it owes plus shareholders’ equity. Hover a block for its value.
TTRX financial health
Descriptive bands, not a rating. Fiscal 2025.
TTRX balance sheet trends, 2022–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Total assets | $2.9M2022 | $12.2M2025 | +61.0%/yr | |
| Total liabilities | $1.8M2022 | $7.5M2025 | +62.0%/yr | |
| Shareholders’ equity | $1.2M2022 | $4.7M2025 | +59.5%/yr | |
| Cash & short-term investments | $2.1M2022 | $5.1M2025 | +34.1%/yr | |
| Total debt | $83,6692022 | $80,3762025 | −1.3%/yr | |
| Net cash (debt) | $2.0M2022 | $5.0M2025 | +$3.0M | |
| Working capital | $401,4422022 | −$806,9802025 | −$1.2M | |
| Book value per share | $0.092022 | $0.342025 | +57.3%/yr | |
| Current ratio | 1.232022 | 0.872025 | −0.37 | |
| Debt / equity | 0.072022 | 0.022025 | −0.06 | |
| Shares outstanding | 13.2M2022 | 13.7M2025 | +1.4%/yr |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
TTRX assets
TTRX liabilities and equity
TTRX debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease obligations.
TTRX balance sheet
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | $5.1M | $872,599 | $1.2M | $2.1M |
| Cash & equivalents | $5.1M | $872,599 | $1.2M | $2.1M |
| Receivables | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Other current assets | $120,300 | $225,325 | $20,820 | $22,473 |
| Total current assets | $5.2M | $1.1M | $1.2M | $2.1M |
| Property, plant & equipment (net) | $78,620 | $120,452 | $33,222 | $81,378 |
| Goodwill & intangible assets | $922,171 | $821,931 | $769,939 | $697,995 |
| Long-term investments | $0 | $0 | $0 | $0 |
| Other non-current assets | $6.0M | $8,582 | $8,582 | $8,582 |
| Total assets | $12.2M | $2.0M | $2.0M | $2.9M |
| Liabilities | ||||
| Accounts payable | $2.9M | — | — | $255,960 |
| Short-term debt | $46,295 | $40,660 | $25,156 | $49,466 |
| Total current liabilities | $6.0M | $707,932 | $489,779 | $1.7M |
| Long-term debt | $0 | $0 | $0 | $0 |
| Lease obligations | $80,376 | $121,036 | $25,156 | — |
| Other long-term liabilities | $1.5M | $1.5M | $1.4M | $34,203 |
| Total liabilities | $7.5M | $2.2M | $1.9M | $1.8M |
| Shareholders' equity | ||||
| Common stock & paid-in capital | $2,943 | $1,342 | $1,324 | $1,317 |
| Retained earnings (deficit) | −$22.4M | −$19.2M | −$17.4M | −$17.2M |
| Total shareholders' equity | $4.7M | −$177,432 | $85,768 | $1.2M |
| Key figures | ||||
| Total debt | $80,376 | $121,036 | $25,156 | $83,669 |
| Net cash (debt) | $5.0M | $751,563 | $1.2M | $2.0M |
| Working capital | −$806,980 | $389,992 | $712,038 | $401,442 |
| Tangible book value | $3.8M | −$999,363 | −$684,171 | $457,199 |
| Book value per share | $0.34 | −$0.01 | $0.01 | $0.09 |
| Shares outstanding | 13.7M | 13.4M | 13.2M | 13.2M |
| Current ratio | 0.87 | 1.55 | 2.45 | 1.23 |
| Quick ratio | 0.85 | 1.23 | 2.41 | 1.22 |
| Debt / equity | 0.02 | — | 0.29 | 0.07 |
| Equity / assets | 38.5% | −8.7% | 4.3% | 39.7% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | |
|---|---|---|---|---|---|
| Assets | |||||
| Cash & short-term investments | $10.3M | $11.2M | $5.1M | $3.1M | $3.2M |
| Cash & equivalents | $10.3M | $11.2M | $5.1M | $3.1M | $3.2M |
| Receivables | $0 | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 |
| Other current assets | $139,688 | $235,171 | $120,300 | $188,583 | $204,018 |
| Total current assets | $10.4M | $11.5M | $5.2M | $3.3M | $3.4M |
| Property, plant & equipment (net) | $56,275 | $67,573 | $78,620 | $89,423 | $99,989 |
| Goodwill & intangible assets | $911,219 | $919,947 | $922,171 | $904,885 | $828,770 |
| Long-term investments | $0 | $0 | $0 | $0 | $0 |
| Other non-current assets | $5.6M | $6.2M | $6.0M | $61,281 | $8,582 |
| Total assets | $17.0M | $18.6M | $12.2M | $4.4M | $4.3M |
| Liabilities | |||||
| Accounts payable | $2.6M | $2.3M | $2.9M | $2.3M | — |
| Short-term debt | $49,329 | $47,795 | $46,295 | $44,829 | $43,405 |
| Total current liabilities | $8.8M | $5.1M | $6.0M | $2.3M | $1.1M |
| Long-term debt | $6.1M | $5.9M | $0 | $0 | $0 |
| Lease obligations | $58,042 | $69,334 | $80,376 | $91,173 | $101,446 |
| Other long-term liabilities | $1.4M | $1.5M | $1.5M | $1.5M | $1.5M |
| Total liabilities | $16.3M | $12.5M | $7.5M | $3.8M | $2.6M |
| Shareholders' equity | |||||
| Common stock & paid-in capital | $2,977 | $2,977 | $2,943 | $2,802 | $1,401 |
| Retained earnings (deficit) | −$29.2M | −$23.4M | −$22.4M | −$22.7M | −$20.8M |
| Total shareholders' equity | $686,888 | $6.1M | $4.7M | $556,718 | $1.8M |
| Key figures | |||||
| Total debt | $6.1M | $6.0M | $80,376 | $91,173 | $101,446 |
| Net cash (debt) | $4.2M | $5.2M | $5.0M | $3.0M | $3.1M |
| Working capital | $1.7M | $6.3M | −$806,980 | $985,486 | $2.3M |
| Tangible book value | −$224,331 | $5.2M | $3.8M | −$348,167 | $945,726 |
| Book value per share | $0.02 | $0.21 | $0.16 | $0.02 | $0.13 |
| Shares outstanding | 29.8M | 29.5M | 29.4M | 28.0M | 13.7M |
| Current ratio | 1.19 | 2.23 | 0.87 | 1.43 | 3.20 |
| Quick ratio | 1.17 | 2.19 | 0.85 | 1.35 | 3.01 |
| Debt / equity | 8.91 | 0.98 | 0.02 | 0.16 | 0.06 |
| Equity / assets | 4.0% | 32.8% | 38.5% | 12.8% | 41.0% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed March 31, 2026); data from EODHD.
TTRX financial position
At the end of fiscal 2025 (December 31, 2025), Turn Therapeutics had total assets of $12.2 million (up 493.6% from a year earlier), total liabilities of $7.5 million and shareholders' equity of $4.7 million. It held $5.1 million in cash and short-term investments against $0.1 million of debt, a net cash position of $5.0 million. Its current ratio was 0.87. In the latest quarter (ended June 30, 2026) total assets were $17.0 million and equity $0.7 million.
Related: TTRX income statement, TTRX cash flow statement, TTRX key metrics. See the TTRX stock overview for the latest quote and news.
TTRX balance sheet FAQ
What are Turn Therapeutics's total assets?
Turn Therapeutics reported total assets of $12.2 million at the end of fiscal 2025 (December 31, 2025), compared with $2.0 million a year earlier.
How much debt does Turn Therapeutics have?
Turn Therapeutics had $0.1 million of total debt at the end of fiscal 2025, including short-term borrowings and lease obligations. Its debt-to-equity ratio was 0.02.
How much cash does Turn Therapeutics have?
Turn Therapeutics held $5.1 million in cash and short-term investments at the end of fiscal 2025; with $0.1 million of debt that is net cash of $5.0 million.
What is Turn Therapeutics's book value?
Turn Therapeutics's shareholders' equity (book value) was $4.7 million at the end of fiscal 2025, or $0.34 per share.
What is Turn Therapeutics's current ratio?
Turn Therapeutics had current assets of $5.2 million and current liabilities of $6.0 million, a current ratio of 0.87 (current liabilities exceed current assets).
How much goodwill does Turn Therapeutics have?
Turn Therapeutics carried $0.9 million of goodwill and intangible assets, 7.6% of total assets, at the end of fiscal 2025.